by The global Cardiac Biomarkers Market is estimated to be valued at US$ 9836.55 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cardiac biomarkers are substances released into the blood when the heart is damaged or stressed. They play an important role in diagnosis of acute coronary syndrome and heart failure. Some common cardiac biomarkers assessed are troponin, CK-MB and myoglobin. Testing for cardiac biomarkers improves diagnosis and facilitates timely treatment of cardiovascular diseases.
Market key trends:
Miniaturization of cardiac biomarker testing is one of the key trends witnessed in the market. Miniaturization enables testing to be conducted at the point-of-care using small volume samples. This reduces turnaround time for results and aids quick clinical decision making. Portable cardia biomarkers testing devices have gained popularity as they facilitate testing outside hospitals and labs. Their small size makes them suitable for use in ambulatory settings and emergency rooms.
Segment Analysis
The Cardiac Biomarkers Market Growth is segmented based on type, application, and end-user. Based on type, the market is segmented into troponin I and T, CK-MB, BNPs, myoglobin, hs-CRP, IMA, and other cardiac biomarkers. The troponin I and T segment dominated the market in 2022 as they are gold standard biomarkers for the detection of heart attacks. They detect even minute damages to the cardiac muscles with high accuracy.
Key Takeaways
The global cardiac biomarkers market is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing incidence of cardiovascular diseases.
Regional analysis
North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to the rising geriatric population, developing healthcare infrastructure, and increasing awareness among people about cardiovascular disorders in the region. Asia Pacific is expected to witness the highest growth rate during the analysis period owing to growing healthcare expenditure and improving healthcare facilities in developing countries such as China and India.
Key players
Key players operating in the cardiac biomarkers market are Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMé rieux SA. Abbott Laboratories dominated the global market in 2022 owing to its robust portfolio of cardiac biomarker testing products. The company has a strong geographic presence across major markets globally.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
